Charles River Laboratories Pre-Tax Profit Margin 2010-2025 | CRL
Current and historical pre-tax profit margin for Charles River Laboratories (CRL) from 2010 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Charles River Laboratories pre-tax profit margin for the three months ending March 31, 2025 was .
| Charles River Laboratories Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2025-03-31 | $4.02B | $0.03B | 0.75% |
| 2024-12-31 | $4.05B | $0.09B | 2.30% |
| 2024-09-30 | $4.06B | $0.52B | 12.78% |
| 2024-06-30 | $4.08B | $0.54B | 13.27% |
| 2024-03-31 | $4.11B | $0.55B | 13.38% |
| 2023-12-31 | $4.13B | $0.58B | 14.10% |
| 2023-09-30 | $4.22B | $0.62B | 14.66% |
| 2023-06-30 | $4.18B | $0.63B | 15.03% |
| 2023-03-31 | $4.09B | $0.64B | 15.72% |
| 2022-12-31 | $3.98B | $0.62B | 15.67% |
| 2022-09-30 | $3.78B | $0.54B | 14.33% |
| 2022-06-30 | $3.69B | $0.54B | 14.70% |
| 2022-03-31 | $3.63B | $0.53B | 14.46% |
| 2021-12-31 | $3.54B | $0.48B | 13.56% |
| 2021-09-30 | $3.43B | $0.49B | 14.24% |
| 2021-06-30 | $3.27B | $0.50B | 15.27% |
| 2021-03-31 | $3.04B | $0.46B | 15.02% |
| 2020-12-31 | $2.92B | $0.45B | 15.25% |
| 2020-09-30 | $2.82B | $0.38B | 13.46% |
| 2020-06-30 | $2.75B | $0.32B | 11.57% |
| 2020-03-31 | $2.72B | $0.29B | 10.76% |
| 2019-12-31 | $2.62B | $0.30B | 11.59% |
| 2019-09-30 | $2.53B | $0.27B | 10.78% |
| 2019-06-30 | $2.45B | $0.27B | 11.14% |
| 2019-03-31 | $2.38B | $0.28B | 11.95% |
| 2018-12-31 | $2.27B | $0.28B | 12.40% |
| 2018-09-30 | $2.14B | $0.28B | 12.84% |
| 2018-06-30 | $2.02B | $0.28B | 13.61% |
| 2018-03-31 | $1.91B | $0.28B | 14.80% |
| 2017-12-31 | $1.86B | $0.30B | 15.99% |
| 2017-09-30 | $1.85B | $0.29B | 15.82% |
| 2017-06-30 | $1.81B | $0.27B | 15.04% |
| 2017-03-31 | $1.77B | $0.25B | 14.04% |
| 2016-12-31 | $1.68B | $0.22B | 13.26% |
| 2016-09-30 | $1.57B | $0.21B | 13.32% |
| 2016-06-30 | $1.49B | $0.21B | 14.01% |
| 2016-03-31 | $1.40B | $0.22B | 15.38% |
| 2015-12-31 | $1.36B | $0.20B | 14.31% |
| 2015-09-30 | $1.34B | $0.19B | 13.82% |
| 2015-06-30 | $1.32B | $0.18B | 13.35% |
| 2015-03-31 | $1.32B | $0.17B | 12.66% |
| 2014-12-31 | $1.30B | $0.18B | 13.71% |
| 2014-09-30 | $1.26B | $0.16B | 12.81% |
| 2014-06-30 | $1.22B | $0.16B | 13.10% |
| 2014-03-31 | $1.17B | $0.15B | 12.45% |
| 2013-12-31 | $1.17B | $0.14B | 11.93% |
| 2013-09-30 | $1.16B | $0.14B | 12.28% |
| 2013-06-30 | $1.14B | $0.13B | 11.11% |
| 2013-03-31 | $1.14B | $0.13B | 11.45% |
| 2012-12-31 | $1.13B | $0.13B | 11.42% |
| 2012-09-30 | $1.14B | $0.14B | 11.92% |
| 2012-06-30 | $1.14B | $0.13B | 11.67% |
| 2012-03-31 | $1.14B | $0.14B | 11.90% |
| 2011-12-31 | $1.14B | $0.13B | 11.72% |
| 2011-09-30 | $1.13B | $-0.27B | -23.99% |
| 2011-06-30 | $1.13B | $-0.31B | -27.06% |
| 2011-03-31 | $1.13B | $-0.33B | -28.90% |
| 2010-12-31 | $1.13B | $-0.34B | -29.54% |
| 2010-09-30 | $1.12B | $0.07B | 6.00% |
| 2010-06-30 | $1.14B | $0.12B | 10.07% |
| 2010-03-31 | $1.16B | $0.14B | 12.06% |
| 2009-12-31 | $1.17B | $0.15B | 12.89% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.107B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $140.286B | 26.31 |
| Elevance Health (ELV) | United States | $88.874B | 11.47 |
| CVS Health (CVS) | United States | $80.430B | 10.00 |
| Cencora (COR) | United States | $56.003B | 19.48 |
| DiDi Global (DIDIY) | China | $23.532B | 35.71 |
| Natera (NTRA) | United States | $22.361B | 0.00 |
| BioMerieux (BMXMF) | France | $16.097B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.999B | 0.00 |
| Solventum (SOLV) | United States | $12.948B | 13.71 |
| CochLear (CHEOY) | Australia | $11.388B | 0.00 |
| ICON (ICLR) | Ireland | $11.234B | 10.44 |
| Doximity (DOCS) | United States | $11.054B | 51.17 |
| Revvity (RVTY) | United States | $10.840B | 18.66 |
| Viatris (VTRS) | United States | $10.223B | 3.51 |
| HealthEquity (HQY) | United States | $9.646B | 42.25 |
| Avantor (AVTR) | United States | $8.906B | 12.94 |
| Medpace Holdings (MEDP) | United States | $8.522B | 22.63 |
| Sonic Healthcare (SKHHY) | Australia | $8.301B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| BrightSpring Health Services (BTSG) | United States | $4.201B | 38.89 |
| Bausch + Lomb (BLCO) | Canada | $4.139B | 24.38 |
| Sotera Health (SHC) | United States | $3.491B | 19.84 |
| Alignment Healthcare (ALHC) | United States | $3.011B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.972B | 38.65 |
| Concentras Parent (CON) | United States | $2.824B | 16.32 |
| Organon (OGN) | United States | $2.485B | 2.64 |
| Ardent Health Partners (ARDT) | United States | $2.126B | 9.06 |
| GeneDx Holdings (WGS) | United States | $2.056B | 79.20 |
| Premier (PINC) | United States | $1.889B | 14.33 |
| Progyny (PGNY) | United States | $1.858B | 40.91 |
| PACS (PACS) | United States | $1.591B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.457B | 29.14 |
| Teladoc Health (TDOC) | United States | $1.275B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.210B | 9.21 |
| Establishment Labs Holdings (ESTA) | $1.099B | 0.00 | |
| CareDx (CDNA) | United States | $1.087B | 16.97 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.894B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.808B | 7.56 |
| QDM (QDMI) | Hong Kong, SAR China | $0.755B | 0.00 |
| Nutex Health (NUTX) | United States | $0.678B | 10.26 |
| LifeMD (LFMD) | United States | $0.578B | 0.00 |
| Embecta (EMBC) | United States | $0.572B | 3.85 |
| Enhabit (EHAB) | United States | $0.547B | 45.00 |
| InnovAge Holding (INNV) | United States | $0.543B | 0.00 |
| SBC Medicals (SBC) | United States | $0.489B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.482B | 10.85 |
| Sonida Senior Living (SNDA) | United States | $0.478B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.449B | 0.00 |
| Oncology Institute (TOI) | United States | $0.248B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.244B | 0.00 |
| Beauty Health (SKIN) | United States | $0.202B | 0.00 |
| DocGo (DCGO) | United States | $0.156B | 25.50 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| KindlyMD (NAKA) | United States | $0.096B | 0.00 |
| So-Young (SY) | China | $0.092B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.089B | 0.00 |
| OncoCyte (OCX) | United States | $0.085B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.073B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.065B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.058B | 0.00 |
| ModivCare (MODV) | United States | $0.057B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.056B | 0.00 |
| Biodesix (BDSX) | United States | $0.044B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |